Explore our on-the-ground coverage of the first day of ACC.22.

Day 2 of ACC.22 was jam-packed with late-breaking clinical trials. Read our quick rundown of what researchers shared with the public for the very first time. 

The new recommendations went live just ahead of ACC.22. They can be read in full in the Journal of the American College of Cardiology, Circulation or Journal of Cardiac Failure.

The issue, identified during a routine inspection, appears to be related to a change in the manufacturing process. It has now been corrected, Medtronic said in a statement. 

The new findings, based on data from nearly 500,000 patients, were presented during ACC.22.

“I am concerned by the FDA’s slow action, over multiple administrations, to protect patients from this product despite early warning signs,” one U.S. representative said in an open letter. 

The new analysis, published in the Journal of the American Heart Association, included patient data from the last three decades. 

Experts urged physicians to take extra protective measures when in the presence of metal protheses during procedures and to be vigilant in shielding their eyes from additional exposure. 

Those include Radiology Partners, Solis Mammography, Cleveland Clinic, Stanford Health Care and Intermountain, among others, the college announced Thursday.